Short-Chain Fatty Acid (SCFA) as a Connecting Link between Microbiota and Gut-Lung Axis-A Potential Therapeutic Intervention to Improve Lung Health.
Level 5 - mechanism / opinion, no new human data
Narrative review detailing proposed biological mechanisms and literature without systematic review methodology or new empirical human data.
PubMed 38585101 · doi:10.1021/acsomega.3c05846
What was done
This paper is a narrative review summarizing existing literature on the gut-lung axis, focusing on how gut microbial metabolites—specifically short-chain fatty acids (SCFAs)—interact with airway immunity and modulate respiratory disease severity, including potential therapeutic strategies like prebiotics, probiotics, and fecal microbiota transplantation.
What was found
The abstract describes proposed biological mechanisms rather than quantitative clinical data; no numerical results or effect estimates are reported. It describes that SCFAs suppress pulmonary inflammation by activating G protein-coupled receptors (free fatty acid receptors) and inhibiting histone deacetylase, influencing immune programming and inflammatory gene expression in pulmonary leukocytes.
Why it matters
It provides a conceptual overview of the gut-lung axis, highlighting how dietary or microbial interventions targeting gut-derived metabolites could serve as adjunct therapeutic strategies in acute and chronic lung conditions, including viral infections.
Limits
The abstract provides no original experimental data, sample sizes, or quantitative meta-analytic synthesis. As a narrative review, it is prone to selection bias and relies heavily on preclinical mechanistic models that may not translate directly to clinical outcomes in human respiratory disease.
Cited by
- supports Short-chain fatty acids suppress the immune system and inhibit the cytokine storm caused by COVID-19, reducing mortality.